Arena Defends Obesity Drug After Phase III BLOOM Wilts

Like Orexigen’s Contrave, Arena’s lorcaserin meets one of two FDA efficacy standards – enough for approval, but not a roaring success.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet